HIV and AIDS

Human Immunodeficiency Virus and
Acquired Immunodeficiency Syndrome

HIV/AIDS Related Meetings

• Surgeon General's African American Community HIV/AIDS Satellite Conference, November 30, 1999. 

• Adefovir (Gilead Sciences, Inc.) new drug application will be discussed by the FDA Antiviral Drugs Advisory Committee on November 1, 1999.  The meeting will be at the Holiday Inn, Gaithersburg, MD.  The complete notice for the meeting in on the web in Text Format   and PDF format.

• FDA Meetings centered around discussion related to HIV viral resistence testing.
  Blood Products Advisory Committee (BPAC) meeting on September 17, 1999 to discuss regulatory classification of drug sensitivity tests.
  FDA Discussion with the Community about the role of HIV resistence testing in new drug development. This meeting will follow the BPAC meeting on the afternoon of September 17, 1999.  Input from this meeting are expected to contribute to the agenda for the Antiviral Drugs Advisory Committee in November.
  Antiviral Drugs Advisory Committee meeting on November 2 and 3, 1999 to discuss the role of HIV resistance testing in new drug development for HIV/AIDS.

• Ziagen (abacavir sulfate) Antiviral Drug Advisory Committee Meeting announcement, November 2, 1998

• Nitazoxanide (NTZ), Antiviral Drug Advisory Committee Meeting Transcript, May 6, 1998

• Satellite Broadcast Series, Adherence to HIV Therapies: HIV Treatment and Prevention Issues, February 24, 1999, 1-3 EST to take a close look at critical issues in disease management. The broadcast will focus on 1) Initiation, maintenance, and improvement of adherence to the new treatment regimens and 2) Role of HIV prevention in the new era of improved HIV disease management.

• Executive Summary, Thalidomide: Potential Benefits and Risks, An Open Public Scientific Workshop September 9-10, 1997

• Thalidomide: Potential Benefits and Risks, Open Public Scientific Workshop, September 9-10, 1997

• FDA Advisory Committee Information Line

• Community/Patient Representation on FDA Advisory Committees (updated 5/12/97)

• When a Patient Speaks ... Patient Representatives to FDA Advisory Committees

Last revised November 2, 1999
Office of Special Health Issues
E-mail:   oshi@oc.fda.gov
Office of International and Constituent Relations
Food and Drug Administration

Privacy Statement